Trial Profile

A phase 1 trial (PK data) in Endocarditis Infections (EI) to demonstrate intravenous administration of phages for EI and other indications

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Sep 2024 According to a PHAXIAM media release, first clinical results are expected around mid-2025.
15 May 2024 According to a PHAXIAM media release, company has recently initiated the enrolment of a phase 1 study (pharmacokinetic (PK) data) in Endocarditis Infections caused by aureus, its second sponsored clinical trial, to evaluate the safety of intravenous administration (IV) of its anti-S. aureus phages. Preliminary clinical results are expected in 2H 2024. Preliminary PK data from this Phase 1 study in EI anticipated in 3Q 2024.
15 Apr 2024 According to a PHAXIAM Therapeutics media release, first results of the study are expected during the 3Q of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com